Mirae Asset cuts Gland Pharma stake to 2.95% after open market sale

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • Mirae Asset Mutual Fund sold 57,842 Gland Pharma shares on September 28, 2026
  • Stake reduced from 2.99% to 2.95% of total equity capital
  • Remaining holding stands at 4,872,191 shares
  • Sale executed through the open market
powered bylight_fuzz_icon
52295070

*this image is generated using AI for illustrative purposes only.

Gland Pharma Limited saw a reduction in institutional holding as Mirae Asset Mutual Fund sold 57,842 shares in the open market on September 28, 2026. The disposal lowered the fund's equity stake from 2.99% to 2.95%.

The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Mirae Asset Investment Managers (India) Private Limited confirmed the sale via a filing to the Bombay Stock Exchange on September 29, 2026.

Transaction details

The fund reduced its position through an open market sale, with no changes to the company's total share capital or diluted voting capital resulting from the trade. The following table outlines the shift in holdings:

Metric Before Sale After Sale Change
Shares held 4,930,033 4,872,191 -57,842
% of total capital 2.99% 2.95% -0.04%
% of diluted capital 2.96% 2.92% -0.03%

What the numbers show

The reduction represents a marginal adjustment rather than a significant exit. The fund retains a substantial block of 4,872,191 shares, maintaining its status as a notable non-promoter holder. The dilution impact is minimal, with the stake against diluted share capital falling by only 0.03% to 2.92%, indicating the sale did not materially alter the ownership structure relative to potential convertible instruments.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-3.02%-0.59%+0.39%+68.17%+45.12%-21.95%

How might this marginal reduction by Mirae Asset influence the broader institutional sentiment and trading volume for Gland Pharma in the upcoming quarter?

Are there any pending regulatory approvals or clinical trial results for Gland Pharma that could trigger further institutional buying or selling activity?

What is the current valuation multiple of Gland Pharma relative to its peers, and does the 2.95% stake align with typical institutional rebalancing thresholds?

Gland Pharma shares worth ₹29.27 crore change hands in large trade

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • A large-trade signal flagged approximately 1,00,068 Gland Pharma shares changing hands on BSE
  • The trades clustered near ₹2924.55 per share, for a combined value of ₹29.27 crore
  • This is a real-time signal from a trade-scanning system, not a confirmed exchange-reported event
  • Official bulk and block deal disclosures are published by NSE/BSE only after market close
powered bylight_fuzz_icon
51768330

*this image is generated using AI for illustrative purposes only.

Gland Pharma shares flagged a large-trade signal on BSE, with approximately 1,00,068 shares changing hands at ₹2924.55, amounting to a combined value of ₹29.27 crore.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Large-trade signal details

The following table summarises the key parameters of the flagged activity:

Parameter Details
Exchange BSE
Approximate quantity 1,00,068 shares
Trade price ₹2924.55
Combined value ₹29.27 crore

The signal reflects a cluster of trades in Gland Pharma shares printed within a short window at or near ₹2924.55, flagged by a real-time trade-scanning system for size and speed. The activity has not been confirmed by the exchange, and no buyer, seller, broker, or client identity is known at this stage.

What this signal is, and is not

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-3.02%-0.59%+0.39%+68.17%+45.12%-21.95%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

Will the official post-market exchange reports confirm this activity as a block or bulk deal, and what identities might be revealed?

How does the ₹29.27 crore trade value compare to Gland Pharma's recent average daily trading volume, and what does this suggest about liquidity?

What are the upcoming corporate events or regulatory filings for Gland Pharma that could explain such significant institutional interest?

More News on Gland Pharma

1 Year Returns:+45.12%